What's new
  • ICMag with help from Landrace Warden and The Vault is running a NEW contest in November! You can check it here. Prizes are seeds & forum premium access. Come join in!

:::::::USA Set to Reschedule Cannabis::::::: HHS Releases Recommendation Documents:::::::

pipeline

Cannabotanist
ICMag Donor
Veteran

Senate Democrats’ Proposed Changes To Federal Hemp Laws Could ‘Eliminate A Whole Range Of Products,’ Industry Advocate Says​



3b71d81faa493372a683c777756df1f4




Published

on
November 18, 2024


By
Kyle Jaeger






Hemp-Fields-UK-American-Hemp.jpg








Senate Democrats have released the long-awaited text of an agriculture bill that contains several proposed changes to federal hemp laws—including provisions to amend how the legal limit of THC is measured and reducing regulatory barriers for farmers who grow the crop for grain or fiber. But certain stakeholders are concerned that part of the intent of the legislation is to “eliminate a whole range of products” that are now sold in the market.
About six months after publishing an initial summary of the legislation, the Democratic majority on the Senate Agriculture, Nutrition, and Forestry Committee shared the full text of its 2024 Farm Bill on Monday.
One key component of the legislation concerns the definition of hemp. As currently enacted, a crop is considered federally legal hemp if it contains no more than 0.3 percent delta-9 THC by dry weight. That would be revised under the new bill, making it so hemp would have to be tested for “total THC” content, including cannabinoids such as delta-8 THC and THC-A, and not just delta-9.

That could theoretically lead to a significant upheaval of the hemp industry as it has evolved since the crop was federally legalized under the 2018 Farm Bill, restricting not only the varieties of plants that could be cultivated but also the products that would be permitted in the marketplace. Lawmakers have been increasingly targeting intoxicating cannabinoid products that have proliferated in recent years.
The new draft bill would also create a specific definition for “industrial hemp,” which includes fiber, stalks, grain, oil, seeds and other components of the plant that “will not be used in the manufacturing or synthesis of natural or synthetic cannabinoid products.”

People applying for licenses to produce industrial hemp would not be subject to background checks under the proposed legislation. And farmers who are producing industrial hemp could see “relaxed regulatory requirements” such as allowing visual inspections or performance-based sampling methods.
While the Senate committee said in its summary that the draft bill would remove an existing ban “on persons who were previously convicted of a felony relating to a controlled substance from participating in the program or producing hemp,” it’s not immediately clear if that policy made it into the 1,397-page legislation.

Marijuana Moment reached out to the Senate committee for clarification, but a representative was not immediately available.
Another feature of the measure that wasn’t noted in the earlier summary relates to a “certified seed pilot program” that would be established, allowing the secretary of the U.S. Department of Agriculture (USDA) to authorize up to five states or tribal governments to “certify genetic purity and identity” of hemp seed varieties if they’ve been specifically bred to produce plants with no more than 0.3 percent total THC content.
Farmers who use those certified seeds could then apply for an exemption to testing requirements. Those exemptions would expire after three years, but they could reapply. Any states or tribes that are selected to participate in the pilot program would need to develop a regulatory plan for vendors of the certified seeds.

If an industrial hemp producer is found to have grown crops “inconsistent with that license,” with “a culpable mental state greater than negligence,” they would become ineligible to obtain licensure for five years from the date of the violation.
Jonathan Miller, general counsel for the U.S. Hemp Roundtable, told Marijuana Moment that stakeholders are “trying to figure all this out,” with questions remaining about the scope of the restrictions that are being proposed.
“We’re obviously opposed to it, but we don’t know how strongly we’re opposed,” he said. “It’s certainly intended to eliminate a whole range of products, but it could eliminate the whole hemp extract industry.”

That said, Miller noted that it’s widely understood on Capitol Hill that this bill is unlikely to advance to enactment in the remainder of the session, so there will be additional opportunity to amend the legislation.
In May, GOP House leaders released their own draft version of the agriculture legislation, which could also reduce regulatory barriers for certain hemp farmers and scale-back a ban on industry participation by people with prior drug felony convictions.
But under an amendment adopted by the House Agriculture Committee, it would also remove cannabinoids that are “synthesized or manufactured outside of the plant” from the federal definition of legal hemp. The change is backed by prohibitionists as well as some marijuana companies, who’ve described the restriction as a fix to a “loophole” in the 2018 Farm Bill.

The Congressional Research Service (CRS) said in a report in June that hemp provisions included in that spending bill could also “create confusion” for the industry due to a lack of clarity around the type of allowable products.


Anti-drug groups, law enforcement and some health organizations have called on Congress to embrace the ban, arguing that “trying to regulate semi-synthetic cannabinoids will not work.”



In addition to Miller’s amendment in the farm bill, the House Appropriations Committee in July approved a separate spending bill that contains a similar provision to prohibit cannabinoid products such as delta-8 THC and CBD containing any “quantifiable” amount of THC.


Hemp-derived cannabinoids also came up in a recent federal appeals court decision in which judges ruled that cannabinoids derived from hemp, such as THC-O-acetate, indeed qualify as hemp and are legal under the 2018 Farm Bill. In making that ruling, the court rejected the Drug Enforcement Administration’s more restrictive interpretation of the law.



How to address hemp-derived cannabinoids has caused some fractures within the cannabis community, and in some cases marijuana businesses have found themselves on the same side as prohibitionists in pushing a derivatives ban.


Lawmakers and stakeholders have also been eyeing a number of other proposals that could be incorporated into the Farm Bill—and which could come up as proposed amendments as the proposal moves through the legislative process—including measures to free up hemp businesses to legally market products like CBD as dietary supplements or in the food supply.


Also, in September, a Democratic senator introduced a bill that would create a federal regulatory framework for hemp-derived cannabinoids, allowing states to set their own rules for products such as CBD while also empowering the Food and Drug Administration (FDA) to ensure that certain safety standards are met in the marketplace—including making sure that products aren’t marketed to children.



Recent USDA data showed a slight rebound in the hemp economy in 2023—the result of a survey that the department mailed to thousands of farmers across the U.S. in January. The first version of the department’s hemp report was released in early 2022, setting a “benchmark” to compare to as the industry matures.


Meanwhile, USDA announced this month that it is once again delaying enforcement of a rule requiring hemp growers to test their crops exclusively at labs registered with the Drug Enforcement Administration (DEA), citing “setbacks” at the agency that have led to “inadequate” access to such facilities.
 

pipeline

Cannabotanist
ICMag Donor
Veteran
Whats the deal with the USA? Why has there not been a federal legalization bill since the MORE Act of 2022?

They have no problem bringing forth legislation to the table that creates cannabis regulation reforms, so why not discuss medical cannabis? Unless they plan to NOT talk about it. Thats whats happening. They plan to put it off and leave us in the danger zone until forced to by federal agencies who they consider to be authorities . Lawmakers refuse to bring the issue to the table in subversion to their duty to represent the people.

 

pipeline

Cannabotanist
ICMag Donor
Veteran



Politics


GOP Senator Says Marijuana Banking And Rescheduling Are ‘Half-Assed’ Measures, Arguing Cannabis Should Be Legally Regulated Like Alcohol And Tobacco​



3b71d81faa493372a683c777756df1f4




Published

on
November 19, 2024


By
Kyle Jaeger



A GOP senator says marijuana rescheduling and industry banking legislation are “half-assed measures,” and lawmakers should instead focus on legalizing cannabis under a federal regulatory framework similar to alcohol and tobacco. He also argued that hemp-derived products that are available in states across the country are “more harmful” than marijuana itself.


That position distinguishes Sen. Thom Tillis (R-NC) from the vast majority of other members of the Republican caucus who oppose cannabis legalization.


But in an interview with AskAPol that was published on Tuesday, Tillis said “I think we’re reaching a point to where we’ve got to take a look” at comprehensive reform.



The Biden administration’s effort sot reclassify cannabis as a Schedule III drug under the Controlled Substances Act (CSA)—as well as a bipartisan marijuana banking bill that moved through a committee he sits on last year—”are all half-measures—we could even argue half-assed measures,” he said.


“We probably need to look at a federal comprehensive framework to deal with the banking issues and scheduling issues,” Tillis said. “But I think, in my opinion, we need a federal regimen that’s not unlike what we have for tobacco and alcohol, where you authenticate the crops on the front end, you mandate flavorings and delivery methods through the FDA and you allow banking.”



Without creating “one consistent framework” for marijuana, “we’re dancing around the issue,” he said.


Tillis added that he’s doesn’t necessarily mean cannabis needs to be federally legalized, but the federal government should at least play a role in regulating state marijuana markets. And he said he’s “really worried” that if incremental reforms such as rescheduling and banking go forward, “it’s going to be at the expense of people truly understanding the dangers out there” with hemp-derived products such as CBD, which he said “are more harmful than marijuana flower.”



Asked whether he’s support the Secure and Fair Enforcement Regulation (SAFER) Banking Act if it came to a vote now, the senator said “no,” arguing that that enacting the modest banking reform would move Congress “further away from a comprehensive framework.”


“I think all that stuff has its place in a framework that also ensures that you don’t have the cartels making money by getting caught into the supply chain—and they are—and then you’ve got the off-the-books people,” he said.


Tillis voted against a cannabis banking bill in the Senate Banking Committee last year.


In the new AskAPol interview, the senator claimed that California Gov. Gavin Newsom (D) has been “kind of silent on this, because he happens to have a lot of people that are making a lot of money off the books and getting it into the system.”



“It all needs to be regulated, and my focus is on capturing the revenue that we should probably capture through an excise tax and dealing with all the negative consequences,” Tillis said.


The senator first discussed his support for creating a federal regulatory scheme for marijuana in an interview with Green Market Report in July, affirming that there should be a framework that “treats marijuana just like tobacco.”


Despite his position, in April Tillis joined Sen. Ted Budd (R-NC) in asking federal, state and local officials what steps they were taking to enforce marijuana prohibition as an Indian tribe prepared to launch recreational cannabis sales on its lands within North Carolina.



Meanwhile, back in 2017, Tillis also teamed up with bipartisan colleagues on a bill that was meant to ease researchers’ access to marijuana for studies on its medical benefits and require the National Institute on Drug Abuse (NIDA) to develop recommendations for good manufacturing practices for growing and producing cannabis for research.


Making the senator’s comments all the more significant is the fact that his state of North Carolina is among the minority that does not even have a comprehensive medical marijuana program in place.
 
Last edited:

pipeline

Cannabotanist
ICMag Donor
Veteran

DEA Should Be Removed From Marijuana Rescheduling Hearing After Illegally Conspiring With Prohibitionists, Legal Filing Says​



3b71d81faa493372a683c777756df1f4




Published

on
November 19, 2024


By
Kyle Jaeger






A Drug Enforcement Administration (DEA) judge is being asked to remove the agency from its role in an upcoming hearing on the Biden administration’s marijuana rescheduling proposal, with a new legal filing citing alleged statutory violations that include “unlawful” communication with a prohibitionist group.
When the Department of Justice formally proposed moving cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA)—consistent with a recommendation from the U.S. Department of Health and Human Services (HHS)—one aspect stood out: The DEA administrator didn’t sign the notice of proposed rulemaking, breaking with historical precedent on federal scheduling proceedings. Instead, it was signed by Attorney General Merrick Garland.
That was one of several factors that led to a motion being filed with DEA Administrative Law Judge (ALJ) John Mulrooney on Monday, seeking corrective action. It was submitted on behalf of Hemp for Victory and Village Farms International, which were both invited to participate in the rescheduling hearing that’s set to begin next month.

The issue isn’t just that DEA Administrator Anne Milgram declined to sign the proposed rule. Throughout that notice, the agency said it needed additional data on a variety of issues—namely cannabis-related health issues and law enforcement concerns—in order to make a complete assessment. The motion argues that the backwards approach to the rulemaking violates federal statute.
“By waiting until the publication of the [proposed rule]—and thus after DOJ had initiated proceedings under [the CSA]—to flag categories of supposedly ‘necessary data,’ DEA ensured that HHS would not get to respond to that data in its recommendation and evaluation,” the motion says. “Even worse, DEA effectively turned the [proposed rule] into a blueprint for the Prohibitionists it apparently was communicating with behind the scenes.”

Another issue that’s arisen concerns DEA’s selection of witnesses to participate in the December hearing, which was scheduled following a public comment period that saw tens of thousands of submissions—a majority of which favored rescheduling or otherwise pushed for bolder reform such as removing marijuana from the CSA altogether.
Mulrooney, the DEA ALJ appointed to handle the case, recently advised that the agency provided insufficient information about the 25 witnesses who were selected. He ordered the designated participants to fill in the blanks—for example, by making clear where they stand on the question of rescheduling. In doing so, he also pushed back the timeline for the hearing. A preliminary meeting is still set for next month, but it won’t be until early 2025 at least until they get to the merits of the case.

In the new motion filed with Mulrooney’s office, attorneys for the petitioners said DEA’s “lack of transparency” in creating the witness list is “alarming, undemocratic, and betrays notions of good governance.” In some cases, seemingly qualified candidates who requested to participate in the hearing did not receive formal denials. And the list submitted to the ALJ didn’t itemize the requesters or provide information about why they were approved or denied.
“Without knowing who DEA excluded and why, there is no way to assess whether and to what extent the Agency’s decisions are arbitrary and capricious, the subject of bias, or otherwise unlawful,” the filing says. “If, for example, DEA included parties with expertise on a particular topic but only if they opposed the Proposed Rule while also excluding parties with even more expertise on that same topic if they supported the Proposed Rule, then there would be a powerful case to be made that the Agency’s decisions were arbitrary and capricious.”

The filing also argues that by even selecting witnesses in the first place, DEA “usurped” the ALJ’s role as the presiding officer of the hearing.
Among the 25 witnesses that DEA chose to join the hearing was Smart Approaches to Marijuana (SAM), the nation’s leading prohibitionist group. The filing includes screenshots of social media posts where the group’s president, Kevin Sabet, indicated he had private conversations with DEA officials about the rescheduling effort as SAM rallied opposition to the reform and urged the agency to keep marijuana in Schedule I.

One week prior to DOJ’s publication of the proposed rule, Sabet posted on X that he could confirm Milgram wouldn’t sign the notice, citing “two confidential sources inside DEA and another outside DEA with intimate knowledge.”
That and other public disclosures added fuel to this latest motion.
“In light of this evidence of improper ex parte communications between DEA and private parties, this Tribunal must take all steps necessary to ensure that all such communications are discovered and included in the administrative record,” it says. In the relief section of the filing, it also calls on the DEA judge to mandate that records of such communication be preserved.
“Unless and until that happens, there will effectively be two records of these proceedings: one that is public and incomplete and another that is secret, complete, and available only to those in the know. Or as Dr. Sabet put it, those with ‘friends in low places,'” it says.

The motion also cites comments given by SAM Executive Vice President Luke Niforatos, who said during a webinar in June that DEA’s approach to the rescheduling notice offered prohibitionists a “roadmap for how to rebut their own Proposed Rule.”
Niforatos said in a statement to Marijuana Moment on Tuesday that the filing is “whacky” and amounts to “pure legal theater and no substance.”
“While it is an entertaining read, we are certain the filing will be rejected,” he said. “If anything, they have perhaps strengthened the argument for our participation.”

In any case, the latest motion implores the DEA tribunal to “use every tool at its disposal to uncover each instance of improper contact between DEA and prohibitionists and determine whether those contacts influenced the Designated Participants list created by the Administrator.”
“Requiring disclosure of the ex parte contacts is what the law demands, and because sunlight is the best disinfectant, it will restore confidence in these proceedings,” it says.
Ultimately, one of the critical requests attorneys for the cannabis companies behind the motion are making is for DEA to lose its status as the “proponent” of the proposed rule. Because the agency allegedly did not follow statutory rules and improperly selected witnesses, including SAM and other anti-drug groups tied to it, “DEA is the opponent” and “cannot bear the burden of proof in these proceedings.”

It’s unclear whether DEA ALJ Mulrooney has authority to remove the agency itself as the proponent in the hearing. But the motion advises that the judge should instead have DOJ—or alternatively Hemp for Victory—serve as the proponent.
Shane Pennington, a partner at Porter Wright Morris & Arthur, LLP who authored the new brief said that “it is our belief that the DEA cannot lawfully act as the proponent of the Proposed Rule and that its actions throughout the administrative process demonstrate that it opposes the proposed transfer of marijuana to Schedule III and is therefore compromised.”

“Treating the DEA as the proponent of the Proposed Rule would violate [the Administrative Procedures Act] and DEA regulations and render these proceedings a sham,” he said. “Lawyers from the Department of Justice, not the Drug Enforcement Administration, must therefore defend this rule.”
Meanwhile, a marijuana and psychedelics researcher is asking the DEA ALJ to postpone its rescheduling hearing due to the agency’s alleged “improper blocking” of witnesses, while arguing that the process should be halted at least until President-elect Donald Trump’s administration comes into power so it can review the rulemaking.
About a week after Panacea Plant Sciences founder and CEO David Heldreth filed a lawsuit in federal court, requesting an order halting the cannabis rescheduling proceedings, he submitted a motion to the DEA judge on Monday seeking a stay of the upcoming December hearing.

Mulrooney separately rejected a veterans group’s petition to participate in the upcoming rescheduling hearing, which the organization called a “travesty of justice” that excludes key voices that would be affected by the potential policy change.
For what it’s worth, Vice President Kamala Harris said recently that part of the reason for the delay in the administration’s marijuana rescheduling effort is federal bureaucracy that “slows things down,” including at DEA.
In March, Harris also expressed some frustration with the bureaucratic process of rescheduling marijuana, prior to DOJ’s formal recommendation, calling on DEA to expediently finish the job.
While the Biden–Harris administration facilitated the review that led to the DOJ rescheduling proposal, Trump has also voiced support for the reform.
In Congress, numerous lawmakers have shared their own perspectives on the proposed reform with DEA and DOJ since the Schedule III announcement was made.
In August, for example, Sen. Chuck Grassley (R-IA) raised concerns about the Biden administration’s justification for recommending marijuana rescheduling, demanding answers to questions from federal agencies about how they arrived at that decision in what he described as a rushed and unconventional administrative process.

A week earlier, top Democratic senators—including Senate Majority Leader Chuck Schumer (D-NY)—sent a separate letter to DOJ’s Garland and DEA’s Milgram urging the agencies to ”promptly finalize” the rule to reschedule marijuana.
While rescheduling would remove certain research barriers and free up state-licensed cannabis business to take federal tax deductions under the Internal Revenue Service (IRS) code known as 280E, it would not federally legalize marijuana, as the Congressional Research Service (CRS) has made known in multiple recent reports.
Meanwhile, two additional congressional lawmakers have joined the ranks of GOP members who are challenging what they say is the “unusual” process that led the Biden administration to propose rescheduling marijuana, expressing concern about how the review was carried out and demanding answers.
Rep. Doug LaMalfa (R-CA) condemned the Biden administration’s push to reclassify marijuana, as well as legislative efforts to enact bipartisan cannabis banking reform, because he says the policy changes would “prop up this immoral industry” and give a “green light to the evil that comes from drug use.”
Sen. Bill Cassidy (R-LA) also blasted the Biden administration over what he described as repeated refusals from federal agencies to brief Congress on its plans and justification for rescheduling marijuana, which he argues fuels speculation that the proposed policy change is politically motivated.

Similarly, 25 GOP congressional lawmakers sent a public comment letter in July opposing the administration’s planned rescheduling of marijuana, specifically alleging the government’s recommendation was based on politics rather than science.
Read the motion submitted to the DEA judge on the marijuana rescheduling case below:
 

pipeline

Cannabotanist
ICMag Donor
Veteran

pipeline

Cannabotanist
ICMag Donor
Veteran

pipeline

Cannabotanist
ICMag Donor
Veteran
Republicans seem to be on board with medical cannabis, its just the conflict with federal law they have a problem with. Thing is the politicians shouldn't have the authority to allow access to medical cannabis for only certain medical issues. People should be able to make that decision for themself. Should be over the counter for adult-use without prescription. I think that would about fix it, or it would be a start.

Cant wait for the day we can go down to the coffee shop to smoke and play chess all winter. I like the dutch model. :smoke:
 

pipeline

Cannabotanist
ICMag Donor
Veteran
Yeah, don't make someone go through a doctor. Its been determined to be relatively safe and states have already adopted this policy, so they need to loosen up. I think its going to be some blowback though if done too quickly because they maintained a poor policy for so long. Maybe that is part of what is holding back comprehensive reforms which repeal prohibition. .
 
Top